Eli Lilly and Company (NYSE:LLY) Shares Sold by Keb Asset Management LLC

Keb Asset Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 46.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 531 shares of the company’s stock after selling 469 shares during the quarter. Keb Asset Management LLC’s holdings in Eli Lilly and Company were worth $410,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Principal Financial Group Inc. increased its stake in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares during the last quarter. Assetmark Inc. grew its holdings in Eli Lilly and Company by 7.3% in the third quarter. Assetmark Inc. now owns 49,713 shares of the company’s stock valued at $44,043,000 after purchasing an additional 3,397 shares during the period. Field & Main Bank increased its position in Eli Lilly and Company by 0.3% during the third quarter. Field & Main Bank now owns 8,172 shares of the company’s stock worth $7,240,000 after purchasing an additional 27 shares during the last quarter. First Personal Financial Services raised its stake in Eli Lilly and Company by 24.9% during the third quarter. First Personal Financial Services now owns 301 shares of the company’s stock worth $267,000 after purchasing an additional 60 shares during the period. Finally, Sheets Smith Wealth Management boosted its holdings in shares of Eli Lilly and Company by 48.6% in the 3rd quarter. Sheets Smith Wealth Management now owns 13,065 shares of the company’s stock valued at $11,574,000 after purchasing an additional 4,271 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 4.8 %

Shares of NYSE LLY opened at $868.59 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock’s 50 day moving average price is $826.63 and its two-hundred day moving average price is $847.24. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The stock has a market capitalization of $823.57 billion, a P/E ratio of 74.17, a PEG ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has authorized a stock buyback program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on LLY shares. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Wolfe Research assumed coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target for the company. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research note on Friday, January 17th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Finally, Bank of America restated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,007.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.